Search
Inolimomab
go.drugbank.com/drugs/DB15628InvestigationalInolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease.
Covax-19™
go.drugbank.com/drugs/DB15846InvestigationalIt uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).
Protocatechualdehyde
go.drugbank.com/drugs/DB11268ApprovedAlso known as protocatechuic aldehyde, protocatechualdehyde is a naturally-occuring phenolic aldehyde that is found in barley, green cavendish bananas, grapevine leaves and root of the herb S. miltiorrhiza
Davunetide
go.drugbank.com/drugs/DB12613InvestigationalDavunetide has been used in trials studying the treatment of Progressive Nonfluent Aphasia, Progressive Supranuclear Palsy, Predicted Tauopathies, Including, Corticobasal Degeneration Syndrome, and Frontotemporal … Davunetide is the first drug to improve memory performance by impacting the mechanisms that lead to physical damage in the brain caused by neurofibrillary tangles, one of the two established pathological
NV1020
go.drugbank.com/drugs/DB04969InvestigationalNV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15682ApprovedInvestigationalAGS-004
go.drugbank.com/drugs/DB05742InvestigationalThis approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.
Saposin C
go.drugbank.com/drugs/DB17380InvestigationalBXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. … Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy.
SynOV1.1
go.drugbank.com/drugs/DB17539InvestigationalSynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. … SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).